Understanding the correct unit of measurement matters for patient safety
Which is better for research: localized or systemic injections for bicep tendonitis
Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,695 followers
Acetyl l-carnitine has showed benefit towards improving attention for people with downs syndrome, Alzheimers disease and migraines, however one study has found it appears safe to use for people with ADHD but has no effect on the overall population, suggesting more studies take place for potential benefits for specific types of the disorder
So when you remove the GLP-1 medication, that patient is set back on a course of weight increase. In other words, without the medication to block and promote pathways that can affect a bodys biochemistry, a person is more likely to return to consuming more calories and regaining weight
